Lavipharm Group’s total earnings before interest, taxes, depreciation, and amortisation (EBITDA) during the First Quarter of 2024 posted an increase of 15.9%, amounting to €2.85 million, up from €2.46 million during Q1 2023.

The Group's EBITDA from continuing operations amounted to €2.51 million, up from €2.47 million.
million in the corresponding period last year. The Group’s EBITDA from discontinued operations includes profits related to the transfer of assets of the wholesaling activity, which was discontinued in January 2024. It should be noted that Q1 2024 includes a non-cash (accounting) entry of €0.34 million for the valuation of personnel stock awards and stock option programs for the period.

Consolidated sales from continuing operations before rebate & clawback reached €15.02 million in Q1 2024, up from €13.7 million in the corresponding quarter of the previous year, posting an increase of 9.7%. First Quarter’s sales do not include the pharmaceutical products Lonarid N® and Lonalgal®, as Lavipharm began sales in May. Likewise, sales of the pharmaceutical product Flagyl® are also excluded, as they are expected to start at the beginning of June.

Gross profit in Q1 2024 amounted to €6.06 million, up from €5.12 million in the corresponding period of 2023, posting an increase of 18.3%. Total net profits after taxes rose to €1.11 million from €0.59 million in the corresponding period last year, for a major increase of 87.1%

Νet borrowing of the Lavipharm Group on March 31, 2024, amounted to €26.1 million. 

In relation to sales, the group's exports recorded an increase of 11.4%, amounting to €6.53 million, compared to €5.86 million in Q1 2023. 

Domestic sales of prescription pharmaceutical products also increased by 5.4%, while over-the-counter (OTC) sales are up by 28.34%. Sales of goods and services to the pharmacy network fell by 8.9%. Other
commercial activities of the Group also showed a decrease of 6.9%.